13 May 2022 | News
GenScript ProBio establishes Korean legal entity and further strengthens cooperation in South Korea and APAC region
Image credit: businesswire
GenScript ProBio, a global CDMO company from GenScript Biotech Corporation, has announced the opening of a legal entity in South Korea.
Since the establishment of GenScript Biotech Corporation and GenScript ProBio, they have been actively exploring in the field of bioprocessing and manufacturing, facilitating bio manufacturing excellence at enhanced speed, reduced cost, and superior quality to support the innovation plans of customers in South Korea, Asia Pacific and around the world, and GenScript ProBio has cooperated with several customers from Korea.
With outstanding technical strength and high-quality CDMO services, GenScript Biotech Corporation received the "Best Contract Development and Manufacturing Organization Award" at the Asia Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive year of GenScript bagging the same award in the Asia Pacific region. The award also followed GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the 'Best Contract Development and Manufacturing Organization Award'.
Dr. Brian Min, CEO of GenScript ProBio said, "South Korea is one of the most dynamic innovation centers of the biotech industry in the Asia-Pacificregion. We are looking forward to working with scientists and partners in South Korea, utilizing GenScript ProBio's one-stop CDMO service platform from drug discovery to commercialization in cell and gene therapy, vaccine, biologics discovery and antibody protein drug, and are committed to improving human life and health."